These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 1699965

  • 1. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
    Geller J.
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
    [Abstract] [Full Text] [Related]

  • 2. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK, Ross M, Tate R, Chisholm GD.
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [Abstract] [Full Text] [Related]

  • 3. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride.
    Geller J, Sionit L.
    J Cell Biochem Suppl; 1992 Feb; 16H():109-12. PubMed ID: 1283893
    [Abstract] [Full Text] [Related]

  • 4. Acute effects of testicular and adrenal cortical blockade on protein synthesis and dihydrotestosterone content of human prostate tissue.
    Liu J, Geller J, Albert J, Kirshner M.
    J Clin Endocrinol Metab; 1985 Jul; 61(1):129-33. PubMed ID: 2581988
    [Abstract] [Full Text] [Related]

  • 5. Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH).
    Geller J, Albert J.
    Urol Res; 1987 Jul; 15(3):151-3. PubMed ID: 3629749
    [Abstract] [Full Text] [Related]

  • 6. Finasteride for benign prostatic hyperplasia.
    Hasinski S, Miller JL, Rose LI.
    Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
    [Abstract] [Full Text] [Related]

  • 7. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
    Stoner E.
    J Steroid Biochem Mol Biol; 1990 Nov 20; 37(3):375-8. PubMed ID: 1701660
    [Abstract] [Full Text] [Related]

  • 8. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
    Zhao XF, Yang Y, Wang W, Qiu Z, Zhang P, Wang B.
    Chin Med J (Engl); 2013 Feb 20; 126(4):711-5. PubMed ID: 23422194
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
    Mendoza P, Sánchez C, Contreras HR, Vergara J, Acevedo C, Cabezas J, Huidobro C, Noé G, Castellón EA.
    Int J Androl; 2009 Dec 20; 32(6):607-15. PubMed ID: 18637152
    [Abstract] [Full Text] [Related]

  • 10. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
    George FW.
    Endocrinology; 1997 Mar 20; 138(3):871-7. PubMed ID: 9048585
    [Abstract] [Full Text] [Related]

  • 11. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
    McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E.
    J Clin Endocrinol Metab; 1992 Mar 20; 74(3):505-8. PubMed ID: 1371291
    [Abstract] [Full Text] [Related]

  • 12. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency.
    Imperato-McGinley J, Shackleton C, Orlic S, Stoner E.
    J Clin Endocrinol Metab; 1990 Mar 20; 70(3):777-82. PubMed ID: 1689740
    [Abstract] [Full Text] [Related]

  • 13. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
    Stanczyk FZ, Azen CG, Pike MC.
    J Steroid Biochem Mol Biol; 2013 Nov 20; 138():10-6. PubMed ID: 23474436
    [Abstract] [Full Text] [Related]

  • 14. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
    Imperato-McGinley J, Gautier T, Cai LQ, Yee B, Epstein J, Pochi P.
    J Clin Endocrinol Metab; 1993 Feb 20; 76(2):524-8. PubMed ID: 8381804
    [Abstract] [Full Text] [Related]

  • 15. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia.
    Guess HA, Heyse JF, Gormley GJ.
    Prostate; 1993 Feb 20; 22(1):31-7. PubMed ID: 7678930
    [Abstract] [Full Text] [Related]

  • 16. Effect of megestrol acetate (Megace) on steroid metabolism and steroid-protein binding in the human prostate.
    Geller J, Albert J, Geller S, Lopez D, Cantor T, Yen S.
    J Clin Endocrinol Metab; 1976 Nov 20; 43(5):1000-8. PubMed ID: 62759
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies.
    Imperato-McGinley J, Sanchez RS, Spencer JR, Yee B, Vaughan ED.
    Endocrinology; 1992 Sep 20; 131(3):1149-56. PubMed ID: 1324152
    [Abstract] [Full Text] [Related]

  • 18. The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat.
    George FW, Johnson L, Wilson JD.
    Endocrinology; 1989 Nov 20; 125(5):2434-8. PubMed ID: 2551651
    [Abstract] [Full Text] [Related]

  • 19. Effect of antiandrogen and/or antiestrogen blockade on human prostate epithelial and stromal cell protein synthesis.
    Geller J, Liu J, Albert J, Fay W, Berry CC.
    J Steroid Biochem; 1986 Nov 20; 25(5B):759-63. PubMed ID: 2433506
    [Abstract] [Full Text] [Related]

  • 20. Differential effect of 5 alpha-reductase inhibition and castration on androgen-regulated gene expression in rat prostate.
    Rittmaster RS, Magor KE, Manning AP, Norman RW, Lazier CB.
    Mol Endocrinol; 1991 Jul 20; 5(7):1023-9. PubMed ID: 1719382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.